The Road Back Program   HOME   MEDICATIONS   PROGRAM   SUPPLEMENTS   ABOUT US   CONTACT

Trazodone Withdrawal

If you are new to The Road Back and want more information before you begin, click Program at the top of this page and you will have free access to How to Get Off Psychoactive Drugs Safely.

If you are experiencing brain zaps, electrical jolts in the head, click here

Trazodone is a medication that is primarily used to treat depression, anxiety, and insomnia. While it is generally considered safe and effective, some individuals may experience withdrawal symptoms when they stop taking the medication. Trazodone withdrawal can be uncomfortable and even dangerous, especially if it is not managed properly.

The symptoms of trazodone withdrawal can vary from person to person and can range from mild to severe. Some of the most common symptoms of trazodone withdrawal include:

Anxiety: Anxiety is one of the most common symptoms of trazodone withdrawal. People may experience feelings of nervousness, restlessness, or fear.

Insomnia: Trazodone is commonly used to treat insomnia, so it is not surprising that people may experience difficulty sleeping when they stop taking the medication.

Dizziness: Dizziness and lightheadedness are also common symptoms of trazodone withdrawal. People may feel unsteady on their feet or as if the room is spinning.

Nausea and vomiting: Some people may experience nausea, vomiting, or diarrhea when they stop taking trazodone.

Headaches: Headaches and migraines are also common symptoms of trazodone withdrawal.

Sweating: Sweating and other flu-like symptoms are also possible when withdrawing from trazodone.

Irritability: People may feel more irritable or short-tempered when they stop taking trazodone.

Muscle aches and pains: Muscle aches and pains can also occur during trazodone withdrawal.

In some cases, the symptoms of trazodone withdrawal can be severe and even life-threatening. Severe withdrawal symptoms can include seizures, hallucinations, and delirium. If you are experiencing any of these symptoms, it is important to seek medical attention immediately.

Trazodone and JNK Gene

One gene that has been of particular interest is the JNK gene. JNK (c-Jun N-terminal kinase) is a group of proteins that play a crucial role in regulating cell growth, survival, and apoptosis (programmed cell death). JNK activation has been linked to various diseases, including cancer, diabetes, and neurodegenerative disorders. Therefore, understanding how JNK is regulated is of great importance.

Several studies have investigated the potential effects of trazodone on JNK expression and activity. In one study, researchers found that trazodone treatment in cultured cells resulted in a significant decrease in JNK activity. The researchers also observed that trazodone inhibited the expression of genes that are regulated by JNK, such as c-Jun and ATF2. These findings suggest that trazodone may have potential therapeutic benefits for diseases associated with JNK activation.

Another study investigated the effects of trazodone on JNK signaling in rats. The researchers found that trazodone treatment resulted in a significant decrease in JNK activity in the brain. This reduction in JNK activity was associated with an improvement in depressive-like behaviors in the rats. The study suggests that trazodone may have antidepressant effects by modulating JNK signaling in the brain.

In addition to its effects on JNK, trazodone has also been shown to modulate the expression of other genes and proteins. For example, trazodone has been shown to increase the expression of brain-derived neurotrophic factor (BDNF), a protein that plays a key role in neuronal growth and plasticity. Trazodone has also been shown to modulate the expression of genes involved in inflammation and oxidative stress, suggesting that it may have potential benefits for a wide range of diseases.

In conclusion, trazodone is an antidepressant medication that has been shown to modulate the expression and activity of various genes and proteins, including JNK. The potential therapeutic benefits of trazodone for diseases associated with JNK activation warrant further investigation. Additionally, the modulation of other genes and proteins by trazodone highlights its potential as a multifaceted therapeutic agent. Further research is needed to fully understand the mechanisms of action of trazodone and its potential benefits for a wide range of diseases.

Trazodone and Obesity

Trazodone is a medication that is primarily used to treat depression, anxiety, and insomnia. However, it has also been studied for its potential effects on obesity. Obesity is a complex condition that is caused by a combination of genetic, environmental, and behavioral factors. It is characterized by an excessive accumulation of body fat that can lead to serious health problems such as heart disease, diabetes, and stroke.

One of the potential mechanisms by which trazodone may impact obesity is through its effect on appetite and food intake. Trazodone has been shown to increase levels of the neurotransmitter serotonin in the brain. Serotonin is known to play a role in regulating appetite and satiety, and drugs that increase serotonin levels are often used to treat obesity. Therefore, trazodone may help to reduce food intake and promote weight loss.

Several studies have investigated the effects of trazodone on body weight and body composition in humans and animals. In one study, researchers compared the effects of trazodone and fluoxetine (another antidepressant medication) on weight gain in depressed patients. The study found that trazodone was associated with less weight gain than fluoxetine. Another study in rats found that trazodone treatment resulted in a decrease in body weight, fat mass, and food intake.

However, not all studies have found a significant effect of trazodone on weight. A review of several studies found that while trazodone may have a small effect on weight loss, it is not a reliable or effective treatment for obesity.

It is important to note that trazodone is not approved by the FDA for the treatment of obesity and should not be used solely for weight loss purposes. Additionally, trazodone can have side effects such as drowsiness, dizziness, and dry mouth, which may limit its usefulness as a weight loss medication.

In conclusion, while trazodone may have some potential for promoting weight loss through its effects on appetite and food intake, it is not a reliable or effective treatment for obesity. It is important to approach weight loss in a comprehensive manner that includes a healthy diet, regular exercise, and behavioral changes. If you are struggling with obesity or weight management, it is important to talk to your healthcare provider about the best treatment options for you.

1. Otani K, Tanaka O, Kaneko S, Ishida M, Yasui N, Fukushima Y, “Mechanisms of the development of trazodone withdrawal symptoms.” International Clinical Pharmacology Journal [Internet] 1994 Summer  [cited 2023 May 8]

2. Jarema M, Dudek D, Landowski J, Heitzman J, Rabe-Jablonska J, Rybakowski J, “Trazodon — the antidepressant: mechanism of action and its position in the treatment of depression.” Polish Journal of Psychiatry 2011 Jul-Aug   [cited 2023 May 8]

3. FDA trazodone label, “Highlights of Prescribing Information“, Revised 2017 Jun  [cited 2023 May 8]

4. Jaffer KY, Chang T, Vanle B, Dang J, Steiner A, Loera N, et al., “Trazodone for Insomnia: A Systematic Review.” Innovations in Clinical Neuroscience 2017 Jul-Aug  [cited 2023 May 8]

5. Mendelson W, “A review of the evidence for the safety of trazodone in insomnia.” Journal of Clinical Psychiatry 2005 Apr  [cited 2023 May 8]

6. Shin JJ, Saadabadi A. Trazodone. [Updated 2020 May 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-.Available from: https://www.ncbi.nlm.nih.gov/books/NBK470560/  [cited 2023 May 8]

7. Knobler HY, Itzchaky S, Emanuel D, Mester R, Maizel S. Trazodone-induced mania. Br J Psychiatry. 1986 Dec;149:787-9. doi: 10.1192/bjp.149.6.787. PMID: 3790881  [cited 2023 May 8]

8. Henssler J, Heinz A, Brandt L, Bschor T. Antidepressant Withdrawal and Rebound Phenomena. Dtsch Arztebl Int. 2019 May 17;116(20):355-361. doi: 10.3238/arztebl.2019.0355. PMID: 31288917; PMCID: PMC6637660. [cited 2023 May 8]

9. Montalbetti D, Zis A, “Cholinergic Rebound Following Trazodone Withdrawal.” Journal of Psychopharmacology Feb 88 Vol 8 Issue 1 P.73 [cited 2023 May 8]

10. Lejoyeux M, Adès J. Antidepressant discontinuation: a review of the literature. J Clin Psychiatry. 1997;58 Suppl 7:11-5; discussion 16. PMID: 9219488. [cited 2023 May 8]

11. Lerner A, Klein M, “Dependence, withdrawal, and rebound of CNS drugs – an update.” Oxford Academic Journal: Brain Communications Vol 1 Issue 1 2019  [cited 2023 May 8]

12. FDA label Oleptro (trazodone hydrochloride) extended release tablets [Feb 2010] [cited 2023 May 8]

13. Hengartner MP, Schulthess L, Sorensen A, Framer A. Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum. Ther Adv Psychopharmacol. 2020;10:2045125320980573. Published 2020 Dec 24. doi:10.1177/2045125320980573 [cited 2023 May 8]

14. Bossini L, Coluccia A, Casolaro I, Benbow J, Amodeo G, De Giorgi R, Fagiolini A. Off-Label Trazodone Prescription: Evidence, Benefits and Risks. Curr Pharm Des. 2015;21(23):3343-51. doi: 10.2174/1381612821666150619092236. PMID: 26088119. [cited 2023 May 8]

15. Schwasinger-Schmidt TE, Macaluso M. Other Antidepressants. Handb Exp Pharmacol. 2019;250:325-355. doi: 10.1007/164_2018_167. PMID: 30194544. [cited 2023 May 8]

16. Gonçalo AMG, Vieira-Coelho MA. The effects of trazodone on human cognition: a systematic review. Eur J Clin Pharmacol. 2021 Jun 7:1–15. doi: 10.1007/s00228-021-03161-6. Epub ahead of print. PMID: 34097124; PMCID: PMC8182348. [cited 2023 May 8]

17. Fagiolini A, Comandini A, Catena Dell’Osso M, Kasper S. Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs. 2012 Dec;26(12):1033-49. doi: 10.1007/s40263-012-0010-5. Erratum in: CNS Drugs. 2013 Aug;27(8):677. PMID: 23192413; PMCID: PMC3693429. [cited 2023 May 8]

18. Lefkowitz D, Kilgo G, Lee S. Seizures and Trazodone Therapy. Arch Gen Psychiatry. 1985;42(5):523. doi:10.1001/archpsyc.1985.01790280105012 [cited 2023 May 8]

19. Volpi-Abadie J, Kaye AM, Kaye AD. Serotonin syndrome. Ochsner J. 2013;13(4):533-540. [cited 2023 May 8]

20. Bijl D. The serotonin syndrome. Neth J Med. 2004 Oct;62(9):309-13. PMID: 15635814. [cited 2023 May 8]

21. Bossini L, Casolaro I, Koukouna D, Cecchini F, Fagiolini A. Off-label uses of trazodone: a review. Expert Opin Pharmacother. 2012 Aug;13(12):1707-17. doi: 10.1517/14656566.2012.699523. Epub 2012 Jun 20. PMID: 22712761. [cited 2023 May 8]

22. FDA label Trazodone hydrochloride tablets for oral use. Approval 1981 [cited 2023 May 8]

23. Jackson E, Shoemaker R, Larian N, Cassis L. Adipose Tissue as a Site of Toxin Accumulation [published correction appears in Compr Physiol. 2018 Jun 18;8(3):1251]. Compr Physiol. 2017;7(4):1085-1135. Published 2017 Sep 12. doi:10.1002/cphy.c160038 [cited 2023 May 8]

24. Roth AJ, McCall WV, Liguori A. Cognitive, psychomotor and polysomnographic effects of trazodone in primary insomniacs. J Sleep Res. 2011 Dec;20(4):552-8. doi: 10.1111/j.1365-2869.2011.00928.x. Epub 2011 May 30. PMID: 21623982; PMCID: PMC3165092. [cited 2023 May 8]

25. Friedmann PD, Rose JS, Swift R, Stout RL, Millman RP, Stein MD. Trazodone for sleep disturbance after alcohol detoxification: a double-blind, placebo-controlled trial. Alcohol Clin Exp Res. 2008;32(9):1652-1660. doi:10.1111/j.1530-0277.2008.00742.x [cited 2023 May 8]

26. Bryant SG, Ereshefsky L. Antidepressant properties of trazodone. Clin Pharm. 1982 Sep-Oct;1(5):406-17. PMID: 6764164.[cited 2023 May 8]